• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

患者来源类器官的代谢谱分析揭示核苷酸合成是恶性横纹肌样肿瘤的一种代谢弱点。

Metabolic profiling of patient-derived organoids reveals nucleotide synthesis as a metabolic vulnerability in malignant rhabdoid tumors.

作者信息

Kes Marjolein M G, Morales-Rodriguez Francisco, Zaal Esther A, de Souza Terezinha, Proost Natalie, van de Ven Marieke, van den Heuvel-Eibrink Marry M, Jansen Jeroen W A, Berkers Celia R, Drost Jarno

机构信息

Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; Oncode Institute, Utrecht, the Netherlands; Division Cell Biology, Metabolism & Cancer, Department Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, the Netherlands.

Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; Oncode Institute, Utrecht, the Netherlands.

出版信息

Cell Rep Med. 2025 Jan 21;6(1):101878. doi: 10.1016/j.xcrm.2024.101878. Epub 2024 Dec 20.

DOI:10.1016/j.xcrm.2024.101878
PMID:39708810
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11866552/
Abstract

Malignant rhabdoid tumor (MRT) is one of the most aggressive childhood cancers for which no effective treatment options are available. Reprogramming of cellular metabolism is an important hallmark of cancer, with various metabolism-based drugs being approved as a cancer treatment. In this study, we use patient-derived tumor organoids (tumoroids) to map the metabolic landscape of several pediatric cancers. Combining gene expression analyses and metabolite profiling using mass spectrometry, we find nucleotide biosynthesis to be a particular vulnerability of MRT. Treatment of MRT tumoroids with de novo nucleotide synthesis inhibitors methotrexate (MTX) and BAY-2402234 lowers nucleotide levels in MRT tumoroids and induces apoptosis. Lastly, we demonstrate in vivo efficacy of MTX in MRT patient-derived xenograft (PDX) mouse models. Our study reveals nucleotide biosynthesis as an MRT-specific metabolic vulnerability, which can ultimately lead to better treatment options for children suffering from this lethal pediatric malignancy.

摘要

恶性横纹肌样肿瘤(MRT)是最具侵袭性的儿童癌症之一,目前尚无有效的治疗方案。细胞代谢重编程是癌症的一个重要特征,多种基于代谢的药物已被批准用于癌症治疗。在本研究中,我们使用患者来源的肿瘤类器官(肿瘤oids)来描绘几种儿童癌症的代谢图谱。结合基因表达分析和质谱代谢物谱分析,我们发现核苷酸生物合成是MRT的一个特别脆弱点。用从头核苷酸合成抑制剂甲氨蝶呤(MTX)和BAY-2402234处理MRT肿瘤oids可降低MRT肿瘤oids中的核苷酸水平并诱导细胞凋亡。最后,我们在MRT患者来源的异种移植(PDX)小鼠模型中证明了MTX的体内疗效。我们的研究揭示了核苷酸生物合成是MRT特有的代谢脆弱点,这最终可能为患有这种致命儿童恶性肿瘤的儿童带来更好的治疗选择。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7f5/11866552/9c15cd6e05aa/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7f5/11866552/ba45615f48b3/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7f5/11866552/bf6037f056d4/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7f5/11866552/fc0d23861862/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7f5/11866552/e5c2ecf80f75/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7f5/11866552/9c15cd6e05aa/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7f5/11866552/ba45615f48b3/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7f5/11866552/bf6037f056d4/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7f5/11866552/fc0d23861862/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7f5/11866552/e5c2ecf80f75/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7f5/11866552/9c15cd6e05aa/gr4.jpg

相似文献

1
Metabolic profiling of patient-derived organoids reveals nucleotide synthesis as a metabolic vulnerability in malignant rhabdoid tumors.患者来源类器官的代谢谱分析揭示核苷酸合成是恶性横纹肌样肿瘤的一种代谢弱点。
Cell Rep Med. 2025 Jan 21;6(1):101878. doi: 10.1016/j.xcrm.2024.101878. Epub 2024 Dec 20.
2
Organoid-based drug screening reveals neddylation as therapeutic target for malignant rhabdoid tumors.基于类器官的药物筛选揭示了泛素化作为恶性横纹肌样肿瘤的治疗靶点。
Cell Rep. 2021 Aug 24;36(8):109568. doi: 10.1016/j.celrep.2021.109568.
3
Somatic mutations and single-cell transcriptomes reveal the root of malignant rhabdoid tumours.体细胞突变和单细胞转录组揭示恶性横纹肌样肿瘤的根源。
Nat Commun. 2021 Mar 3;12(1):1407. doi: 10.1038/s41467-021-21675-6.
4
MDM2 and MDM4 Are Therapeutic Vulnerabilities in Malignant Rhabdoid Tumors.MDM2 和 MDM4 是恶性横纹肌样瘤的治疗靶点。
Cancer Res. 2019 May 1;79(9):2404-2414. doi: 10.1158/0008-5472.CAN-18-3066. Epub 2019 Feb 12.
5
CD146 is a novel marker for highly tumorigenic cells and a potential therapeutic target in malignant rhabdoid tumor.CD146是高致瘤性细胞的一种新型标志物,也是恶性横纹肌样瘤的一个潜在治疗靶点。
Oncogene. 2016 Oct 6;35(40):5317-5327. doi: 10.1038/onc.2016.72. Epub 2016 Apr 4.
6
Antitumor activity of gefitinib in malignant rhabdoid tumor cells in vitro and in vivo.吉非替尼在恶性横纹肌样瘤细胞中的体内外抗肿瘤活性。
Clin Cancer Res. 2004 Sep 1;10(17):5940-8. doi: 10.1158/1078-0432.CCR-04-0192.
7
Etodolac, a selective cyclooxygenase-2 inhibitor, induces apoptosis by activating caspases in human malignant rhabdoid tumor cells (FRTK-1).依托度酸,一种选择性环氧化酶-2抑制剂,通过激活半胱天冬酶在人恶性横纹肌样瘤细胞(FRTK-1)中诱导细胞凋亡。
Oncol Rep. 2007 Jan;17(1):169-73.
8
Unbiased Metabolic Profiling Predicts Sensitivity of High MYC-Expressing Atypical Teratoid/Rhabdoid Tumors to Glutamine Inhibition with 6-Diazo-5-Oxo-L-Norleucine.无偏代谢组学预测高 MYC 表达的非典型畸胎瘤/横纹肌样瘤对 6-叠氮-5-氧-L-正亮氨酸的谷氨酰胺抑制的敏感性。
Clin Cancer Res. 2019 Oct 1;25(19):5925-5936. doi: 10.1158/1078-0432.CCR-19-0189. Epub 2019 Jul 12.
9
SMARCB1 loss activates patient-specific distal oncogenic enhancers in malignant rhabdoid tumors.SMARCB1 缺失激活恶性横纹肌样肿瘤中患者特异性的远端致癌增强子。
Nat Commun. 2023 Dec 1;14(1):7762. doi: 10.1038/s41467-023-43498-3.
10
Insulin-like growth factor 2 axis supports the serum-independent growth of malignant rhabdoid tumor and is activated by microenvironment stress.胰岛素样生长因子2轴支持恶性横纹肌样瘤的血清非依赖性生长,并被微环境应激激活。
Oncotarget. 2017 Jul 18;8(29):47269-47283. doi: 10.18632/oncotarget.17617.

引用本文的文献

1
SMARCB1 Deficiency as a Driver of the Hallmarks of Cancer in Rhabdoid Tumours: Novel Insights into Dysregulated Energy Metabolism, Emerging Targets, and Ongoing Clinical Trials.SMARCB1缺陷作为横纹肌肉瘤中癌症特征的驱动因素:对能量代谢失调、新出现的靶点及正在进行的临床试验的新见解
Metabolites. 2025 May 3;15(5):304. doi: 10.3390/metabo15050304.

本文引用的文献

1
Bridging the gap: advancing cancer cell culture to reveal key metabolic targets.缩小差距:推进癌细胞培养以揭示关键代谢靶点。
Front Oncol. 2024 Sep 17;14:1480613. doi: 10.3389/fonc.2024.1480613. eCollection 2024.
2
Gemcitabine therapeutically disrupts essential SIRT1-mediated p53 repression in atypical teratoid/rhabdoid tumors.替莫唑胺在治疗上破坏了非典型畸胎瘤/横纹肌样瘤中 SIRT1 介导的 p53 抑制作用。
Cell Rep Med. 2024 Sep 17;5(9):101700. doi: 10.1016/j.xcrm.2024.101700. Epub 2024 Aug 28.
3
Metabolic reprogramming of clear cell renal cell carcinoma.
透明细胞肾细胞癌的代谢重编程。
Front Endocrinol (Lausanne). 2023 Jun 6;14:1195500. doi: 10.3389/fendo.2023.1195500. eCollection 2023.
4
Pancreatic tumors exhibit myeloid-driven amino acid stress and upregulate arginine biosynthesis.胰腺肿瘤表现出髓系驱动的氨基酸应激,并上调精氨酸生物合成。
Elife. 2023 May 31;12:e81289. doi: 10.7554/eLife.81289.
5
PI3K/AKT/mTOR Dysregulation and Reprogramming Metabolic Pathways in Renal Cancer: Crosstalk with the VHL/HIF Axis.PI3K/AKT/mTOR 失调与肾癌代谢途径重编程:与 VHL/HIF 轴的串扰。
Int J Mol Sci. 2023 May 7;24(9):8391. doi: 10.3390/ijms24098391.
6
Atypical teratoid/rhabdoid tumoroids reveal subgroup-specific drug vulnerabilities.非典型畸胎样/横纹肌样肿瘤样病灶揭示亚组特异性药物脆弱性。
Oncogene. 2023 May;42(20):1661-1671. doi: 10.1038/s41388-023-02681-y. Epub 2023 Apr 5.
7
Cancer-selective metabolic vulnerabilities in MYC-amplified medulloblastoma.MYC 扩增的髓母细胞瘤中癌症选择性代谢弱点
Cancer Cell. 2022 Dec 12;40(12):1488-1502.e7. doi: 10.1016/j.ccell.2022.10.009. Epub 2022 Nov 10.
8
DHODH inhibition impedes glioma stem cell proliferation, induces DNA damage, and prolongs survival in orthotopic glioblastoma xenografts.二氢乳清酸脱氢酶(DHODH)抑制可阻碍胶质瘤干细胞增殖,诱导DNA损伤,并延长原位胶质母细胞瘤异种移植模型的生存期。
Oncogene. 2022 Dec;41(50):5361-5372. doi: 10.1038/s41388-022-02517-1. Epub 2022 Nov 7.
9
Safety analysis of high-dose methotrexate in pediatric non-Hodgkin lymphomas.儿童非霍奇金淋巴瘤中甲氨蝶呤大剂量治疗的安全性分析。
Pediatr Blood Cancer. 2022 Nov;69(11):e29940. doi: 10.1002/pbc.29940. Epub 2022 Sep 7.
10
De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma.异柠檬酸脱氢酶突变型脑胶质瘤中从头嘧啶合成是一个可靶向的弱点。
Cancer Cell. 2022 Sep 12;40(9):939-956.e16. doi: 10.1016/j.ccell.2022.07.011. Epub 2022 Aug 18.